For: | Subramanian S, Haroutounian S, Palanca B, Lenze EJ. Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence. Journal of the Neurological Sciences 2022. [DOI: 10.1016/j.jns.2022.120152] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis] |
---|
Number | Citing Articles |
1 | Nguyen TML, Defaix C, Mendez-David I, Tritschler L, Etting I, Alvarez JC, Choucha W, Colle R, Corruble E, David DJ, Gardier AM. Intranasal (R, S)-ketamine delivery induces sustained antidepressant effects associated with changes in cortical balance of excitatory/inhibitory synaptic activity. Neuropharmacology 2023;225:109357. [PMID: 36462636 DOI: 10.1016/j.neuropharm.2022.109357] [Reference Citation Analysis] |
2 | Zhang YB, Xu D, Bai L, Zhou YM, Zhang H, Cui YL. A Review of Non-Invasive Drug Delivery through Respiratory Routes. Pharmaceutics 2022;14:1974. [PMID: 36145722 DOI: 10.3390/pharmaceutics14091974] [Reference Citation Analysis] |